Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|MINT1526A||MINT1526A is a monoclonal antibody against integrin alpha 5 beta 1 that blocks interaction with extracellular matrix thus potentially leads to tumor cell death (PMID: 29905898).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Advanced Solid Tumor||no benefit||MINT1526A||Phase I||Actionable||In a Phase I trial, MINT1526A monotherapy did not result in partial response in patients with advanced solid tumors (PMID: 29905898).||29905898|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT01139723||Phase I||Bevacizumab MINT1526A||A Study of the Safety and Pharmacokinetics of MINT1526A, Administered Intravenously As a Single Agent and in Combination With Bevacizumab to Patients With Advanced Solid Tumors||Completed|